ABSTRACT
El antígeno específico de próstata (PSA, del inglés, Prostate Specific Antigen) es una glicoproteína producida por la próstata, y es el marcador tumoral de mayor uso. Sin embargo, su baja especificidad para diferenciar entre cáncer de próstata y otras alteraciones no malignas, como la hipertrofia benigna de la próstata (HBP) y la prostatitis aguda, limitan su utilidad diagnóstica
Prostate Specific Antigen (PSA) is a glycoprotein produced by the prostate and is the most widely used tumor marker. However, its low specificity to differentiate between prostate cancer and other non-malignant conditions, such as benign prostate hypertrophy (BPH) and acute prostatitis, limits its diagnostic utility
Subject(s)
Prostate-Specific Antigen , Prostatic Hyperplasia , Prostatitis , Platelet Membrane Glycoproteins , Biomarkers, TumorABSTRACT
Introducción: La hiperplasia prostática benigna (HPB) es una enfermedad caracterizada por síntomas del tracto urinario inferior (1). Estos síntomas suelen causar un impacto negativo en la calidad de vida del paciente llevándolo a padecer trastornos depresivos (7). Se han encontrado síntomas depresivos hasta en el 22.5% de los pacientes con HPB sin embargo, hay poca evidencia de que estos síntomas disminuyan luego de tratar la HPB (5). Una herramienta útil para medir los síntomas depresivos es la Escala de Medición de Depresión de Hamilton (3). Objetivos: Este estudio pretende evaluar la presencia de síntomas depresivos en pacientes con HPB y comprobar si estos síntomas disminuyen posteriormente al tratamiento quirúrgico para HPB. Métodos. Se utilizó un muestra de 30 pacientes, edad (promedio 67 ± 8 años), sometidos a tratamiento quirúrgico para HPB y quienes presentaran por lo menos un síntoma depresivo según la escala de medición de depresión de Hamilton. Resultados. Todos tuvieron resección transuretral de próstata (RTUP). Previo a la cirugía se encontraron síntomas depresivos en el 76%. Un mes posterior a la cirugía se encontraron síntomas depresivos en 28, sin embargo, se encontró depresión leve en el 23.3% (vs pre op 30%), depresión moderada en el 16.6% (vs pre op 30%) y depresión severa en el 13.3% (vs pre-op 16.6%). La Escala de Medición de Depresión de Hamilton tuvo una puntuación media preoperatoria de 13.93 puntos. Un mes posterior a la cirugía la puntuación media fue de 9.36 puntos. La diferencia fue de 4.56 puntos, lo cual es estadísticamente significativo (P=0.05). Hubo complicaciones quirúrgicas en 3 pacientes quienes tuvieron un aumento en el puntaje postoperatorio y hubo aumento del nivel de depresión. En el estudio 15 refirieron disfunción eréctil previo a la cirugía y únicamente 8 persistieron con disfunción luego de la cirugía. Conclusiones. Los pacientes con HBP constituyen una población en riesgo de padecer síntomas depresivos. Los síntomas depresivos están relacionados con padecer STUI y disfunción eréctil; ambas condiciones afectan la calidad de vida. El tratamiento quirúrgico para tratar la HPB es efectivo en disminuir los síntomas depresivos mejorando la calidad de vida causando mínimos efectos negativos.
Introduction: Benign Prostatic Hyperplasia (BPH) is a condition that leads to inferior urinary tract symptoms (1). These symptoms often cause a negative impact on the quality of life leading to depressive symptoms (7). Depressive symptoms are present in up to 22.5% of patients with BPH, however, there is limited evidence that these symptoms decrease with HPB treatment (5). A useful tool to measure depressive symptoms is the Hamilton Depression Rating Scale (HDRS) (3). Objective: Main purpose of the study is to assess the prevalence of depressive symptoms in patients with BPH and determine whether these symptoms decreased after a corrective surgery. Methods: A sample of 30 male patients, average age 67 ± 8 years old, with surgical treatment indication for BPH, with at least one depressive symptom according to the HDRS was obtained. Results: All patients in the study underwent transurethral resection of the prostate (TURP). Prior to surgery, depressive symptoms found in 76.6%. A month post-surgery depressive symptoms found in 28, however mild depression was present in 23.3% (vs pre-op 30%) moderate depression in 16.6% (vs pre-op 30.0%) and severe depression in 13.3% (vs pre-op 16.6%). Measurement with HDRS had a mean preoperative score 13.93 points; a post-surgery month the average score was 9.36. The difference was 4.56 points; which is statistically significant (P = 0.05). Three patients had surgical complications and they had an increase in postoperative score and also increased in the level of depression. In the study 15 patients reported erectile dysfunction prior to surgery; out of these patients only 8 persisted with dysfunction after surgery. Conclusions: BPH patients is a population at risk for developing depressive symptoms. Depressive symptoms are related to developing lower urinary tract symptoms and erectile dysfunction; both conditions affecting the quality of life. Surgery to treat BPH is effective in reducing depressive symptoms by improving the quality of life and with minimal adverse effects.
ABSTRACT
Objective To study the relationship between IGF-1, IGFBP-3 and prostatic volume (PV) by examining the levels of insulin and insulin-like growth fator-1 (IGF-1) and insulin-like growth factor binding protein-3 ( IGFBP-3 ) and other indicators in patients with impaired glucose regulation and benign prostate hypertrophy. Methods According to 75 g oral glucose tolerance test (OGTT) results, 109 BPH patients aged over 50 years were divided into three groups: normal glucose tolerance (NGT) group (n = 56), impaired fasting glucose (IFG) group (n = 14), impaired glucose tolerance (IGT group, n = 39). The biochemical indicators and postatic hyperplasia related factors and IGF-1, GFBP-3 were measured. Results There were no statistical differences between the three groups in terms of blood lipids, homocysteine, urinary inhibition C, fasting insulin (FINS), glycosylated hemoglobin, IGF-1 and IGFBP-3 (P > 0.05). There were no significant differences between the groups in terms of PV, prostate specific antigen, the quality of life score and the international prostate symptom score (P > 0.05). Fasting plasma glucose and insulin resistance index (HOMA IR) were higher in IFG group than NGT group (P′ < 0.017) and IGT group (P′ < 0.017). 2-hour plasma glucose and 2-hour insulin were higher in IGT group than NGT group (P′ < 0.017) and IFG group (P′ < 0.017). PV was positively correlated with FINS but not correlated with IGF-1, IGFBP- 3 by multiple multiple step wise regression analysis. Conclusion Oyperinsulinemia is a risk factor in the development of BPH with IGR, and IGF-1 and IGFBP-3 are not associated with BPH risk. Further investigation is needed to elucidate the role of the IGF-1 and IGFBP-3 in BPH.
ABSTRACT
Objective:To explore the etiology and prevention of common post-prostatectomy complications,including hemorrhage,wound infection,bladder detrusor muscle instability,incontinence and bladder neck contractures.Methods:The advanced prostatectomy techniques were performed on 114 BPH patients,including the deep 8-shaped suture of prostatic vessels,packet-shaped suture and slinging of bladder neck,a deep and wide V-shaped piece of tissue resected from the heightened posterior part of the bladder neck to avoid tear of the external urethral sphincter during operation period.A#22F three-way Foley urethral catheter for drainage and traction.A multiple hole rubber drain catheter was placed in retropubis,and was implanted 0.125% bupicarine was transfused into epidural continuously by patient controled epidural analgesia (PCEA) post-operatively.Results:Complication rate of patients treated with the above method decreased obviously( P